Nucleic acid aptamer-guided cancer therapeutics and diagnostics: The next generation of cancer medicine

Theranostics

Volumn 5, Issue 1, 2015, Pages 23-42

  Xiang, Dongxi ^a   Shigdar, Sarah ^a   Qiao, Greg ^b   Wang, Tao ^a   Kouzani, Abbas Z ^a   Zhou, Shu Feng ^c   Kong, Lingxue ^a   Li, Yong ^d   Pu, Chunwen ^e   Duan, Wei ^a  

^a DEAKIN UNIVERSITY   (Australia)

^b The University of Melbourne   (Australia)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e DALIAN UNIVERSITY   (China)

Author keywords

Active targeting; Aptamer; Cancer stem cell; Cancer theranostic; Cancer therapy; Chemoresistance

Indexed keywords

APTAMER; ARABINOGALACTAN; AS 1411 APTAMER; CL.42 APTAMER; DNA APTAMER NAS 24; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; LIPOSOME; MACROGOL POLYGLACTIN NANOPARTICLE; MICRORNA; NANOPARTICLE; PACLITAXEL; RAPAMYCIN; RNA APTAMER; RNA INDUCED SILENCING COMPLEX; SGC8C APTAMER; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TLS11A GC APTAMER; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; VIMENTIN; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; BINDING AFFINITY; BREAST CANCER; BRONCHUS CANCER; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CANCER THERAPY; CARDIOTOXICITY; CELL PH; CHEMICAL MODIFICATION; COLON CARCINOMA; COMBINATORIAL CHEMISTRY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONFORMATIONAL TRANSITION; DIAGNOSTIC IMAGING; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESEARCH; DRUG TARGETING; DRUG TRANSPORT; DRUG TUMOR LEVEL; EHRLICH ASCITES TUMOR; ENCAPSULATION; EXTRACELLULAR MATRIX; GLIOMA; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LYMPHOMA; MELANOMA B16; MOLECULARLY TARGETED THERAPY; NANOMEDICINE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGICAL PARAMETERS; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PROSTATE CANCER; QUALITY OF LIFE; RADIOSENSITIVITY; RETINOBLASTOMA; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID TUMOR; SURFACE PROPERTY; TISSUE PRESSURE; TREATMENT RESPONSE; TUMOR BLOOD FLOW; TUMOR CELL DENSITY; TUMOR HETEROGENEITY; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; MEDICAL RESEARCH; NEOPLASMS; PROCEDURES; TRENDS;

ANTINEOPLASTIC AGENTS; APTAMERS, NUCLEOTIDE; BIOMEDICAL RESEARCH; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS;

EID: 84924284243     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.10202     Document Type: Review

References (219)

1. O'Connor ML, Xiang D, Shigdar S, et al. Cancer stem cells: A contentious hypothesis now moving forward. Cancer Lett. 2014; 344: 180-7.
2. Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell. 2014; 54: 716-27.
3. Shigdar S, Macdonald J, O'Connor M, et al. Aptamers as theranostic agents: modifications, serum stability and functionalisation. Sensors. 2013; 13: 13624-37.
4. Chauhan VP, Stylianopoulos T, Boucher Y, et al. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng. 2011; 2: 281-98.
5. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol. 2013; 31: 2205-18.
6. Straw JA, Hart MM, Klubes P, et al. Distribution of anticancer agents in spontaneous animal tumors. I. Regional blood flow and methotrexate distribution in canine lymphosarcoma. J Natl Cancer Inst. 1974; 52: 1327-31.
7. Straw JA, Klubes P, Hart MM. Distribution of anticancer agents in spontaneous animal tumors. II. Distribution of gallium in canine lymphosarcoma. J Natl Cancer Inst. 1975; 55: 199-202.
8. Stacker SA, Williams SP, Karnezis T, et al. Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat Rev Cancer. 2014; 14: 159-72.
9. Fong EL, Santoro M, Farach-Carson MC, et al. Tissue Engineering Perfusable Cancer Models. Curr Opin Chem Eng. 2014; 3: 112-17.
10. Correa de Sampaio P, Auslaender D, Krubasik D, et al. A heterogeneous in vitro three dimensional model of tumor-stroma interactions regulating sprouting angiogenesis. PLoS One. 2012; 7: e30753.
11. Ruddle NH. Lymphatic vessels and tertiary lymphoid organs. J Clin Invest. 2014; 124: 953-9.
12. Karaman S, Detmar M. Mechanisms of lymphatic metastasis. J Clin Invest. 2014; 124: 922-8.
13. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011; 63: 136-51.
14. Taurin S, Nehoff H, Greish K. Anticancer nanomedicine and tumor vascular permeability; Where is the missing link? J Control Release. 2012; 164: 265-75.
15. Hagendoorn J, Tong R, Fukumura D, et al. Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis. Cancer Res. 2006; 66: 3360-4.
16. Welter M, Rieger H. Interstitial fluid flow and drug delivery in vascularized tumors: a computational model. PLoS One. 2013; 8: e70395.
17. Heldin C-H, Rubin K, Pietras K, et al. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer. 2004; 4: 806-13.
18. Ariffin AB, Forde PF, Jahangeer S, et al. Releasing pressure in tumors: what do we know so far and where do we go from here? A review. Cancer Res. 2014; 74: 2655-62.
19. Stylianopoulos T, Martin JD, Snuderl M, et al. Coevolution of solid stress and interstitial fluid pressure in tumors during progression: implications for vascular collapse. Cancer Res. 2013; 73: 3833-41.
20. Heldin CH, Rubin K, Pietras K, et al. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer. 2004; 4: 806-13.
21. Jain RK, Martin JD, Stylianopoulos T. The role of mechanical forces in tumor growth and therapy. Annu Rev Biomed Eng. 2014; 16: 321-46.
22. Nichols JW, Bae YH. EPR: Evidence and fallacy. J Control Release. 2014; 190C: 451-64.
23. Fuso Nerini I, Morosi L, Zucchetti M, et al. Intratumor Heterogeneity and Its Impact on Drug Distribution and Sensitivity. Clin Pharmacol Ther. 2014; 96: 224-38.
24. Liu C, Krishnan, Xu XY. Towards an integrated systems-based modelling framework for drug transport and its effect on tumor cells. J Biol Eng. 2014; 8: 3.
25. Ramanujan S, Pluen A, McKee TD, et al. Diffusion and convection in collagen gels: implications for transport in the tumor interstitium. Biophys J. 2002; 83: 1650-60.
26. Jang SH, Wientjes MG, Lu D, et al. Drug delivery and transport to solid tumors. Pharm Res. 2003; 20: 1337-50.
27. Yang X, Liu X, Liu Z, et al. Near-infrared light-triggered, targeted drug delivery to cancer cells by aptamer gated nanovehicles. Adv Mater. 2012; 24: 2890-5.
28. Matsuo M, Matsumoto S, Mitchell JB, et al. Magnetic Resonance Imaging of the Tumor Microenvironment in Radiotherapy: Perfusion, Hypoxia, and Metabolism. Semin Radiat Oncol. 2014; 24: 210-17.
29. Kharaishvili G, Simkova D, Bouchalova K, et al. The role of cancer-associated fibroblasts, solid stress and other microenvironmental factors in tumor progression and therapy resistance. Cancer Cell Int. 2014; 14: 41.
30. Sheth RA, Hesketh R, Kong DS, et al. Barriers to drug delivery in interventional oncology. J Vasc Interv Radiol. 2013; 24: 1201-7.
31. Fan D, Creemers EE, Kassiri Z. Matrix as an interstitial transport system. Circ Res. 2014; 114: 889-902.
32. Goertz DE, Yu JL, Kerbel RS, et al. High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow. Cancer Res. 2002; 62: 6371-5.
33. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983; 219: 983-5.
34. Azzi S, Hebda JK, Gavard J. Vascular permeability and drug delivery in cancers. Front Oncol. 2013; 3: 211.
35. Chen P, Bonaldo P. Role of macrophage polarization in tumor angiogenesis and vessel normalization: implications for new anticancer therapies. Int Rev Cell Mol Biol. 2013; 301: 1-35.
36. He X, Li J, An S, et al. pH-sensitive drug-delivery systems for tumor targeting. Ther Deliv. 2013; 4: 1499-510.
37. Riemann A, Schneider B, Gundel D, et al. Acidic priming enhances metastatic potential of cancer cells. Pflugers Arch. 2014; doi: 10.1007/s00424-014-1458-6. [Epub ahead of print].
38. Rotin D, Robinson B, Tannock IF. Influence of hypoxia and an acidic environment on the metabolism and viability of cultured cells: potential implications for cell death in tumors. Cancer Res. 1986; 46: 2821-6.
39. Wike-Hooley JL, Haveman J, Reinhold HS. The relevance of tumor pH to the treatment of malignant disease. Radiother Oncol. 1984; 2: 343-66.
40. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature. 1990; 346: 818-22.
41. Shigdar S, Qian C, Lv L, et al. The use of sensitive chemical antibodies for diagnosis: detection of low levels of epcam in breast cancer. PLoS One. 2013; 8: e57613.
42. Cerchia L, de Franciscis V. Targeting cancer cells with nucleic acid aptamers. Trends Biotechnol. 2010; 28: 517-25.
43. Keefe AD, Szostak JW. Functional proteins from a random-sequence library. Nature. 2001; 410: 715-8.
44. Mi J, Liu Y, Rabbani ZN, et al. In vivo selection of tumor-targeting RNA motifs. Nat Chem Biol. 2010; 6: 22-4.
45. Cheng C, Chen YH, Lennox KA, et al. In vivo SELEX for Identification of Brain-penetrating Aptamers. Mol Ther Nucleic Acids. 2013; 2: e67.
46. Colas P. Combinatorial protein reagents to manipulate protein function. Curr Opin Chem Biol. 2000; 4: 54-9.
47. Doggrell SA. Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration. Expert Opin Pharmacother. 2005; 6: 1421-3.
48. Hicke BJ, Stephens AW. Escort aptamers: a delivery service for diagnosis and therapy. J Clin Invest. 2000; 106: 923-8.
49. Shigdar S, Lin J, Yu Y, et al. RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci. 2011; 102: 991-8.
50. Proske D, Blank M, Buhmann R, et al. Aptamers--basic research, drug development, and clinical applications. Appl Microbiol Biotechnol. 2005; 69: 367-74.
51. Bruno JG. A review of therapeutic aptamer conjugates with emphasis on new approaches. Pharmaceuticals (Basel). 2013; 6: 340-57.
52. Meng L, Yang L, Zhao X, et al. Targeted delivery of chemotherapy agents using a liver cancer-specific aptamer. PLoS One. 2012; 7: e33434.
53. Hedden L, O'Reilly S, Lohrisch C, et al. Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer. Oncologist. 2012; 17: 164-71.
54. Jeyakumar A, Younis T. Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations. Clin Med Insights Oncol. 2012; 6: 179-87.
55. Phillips JA, Lopez-Colon D, Zhu Z, et al. Applications of aptamers in cancer cell biology. Anal Chim Acta. 2008; 621: 101-8.
56. Jayasena SD. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem. 1999; 45: 1628-50.
57. Harding FA, Stickler MM, Razo J, et al. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010; 2: 256-65.
58. White RR, Sullenger BA, Rusconi CP. Developing aptamers into therapeutics. J Clin Invest. 2000; 106: 929-34.
59. Drolet DW, Nelson J, Tucker CE, et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res. 2000; 17: 1503-10.
60. Shigdar S, Qiao L, Zhou S-F, et al. RNA aptamers targeting cancer stem cell marker CD133. Cancer Lett. 2013; 330: 84-95.
61. Shigdar S, Ward AC, De A, et al. Clinical applications of aptamers and nucleic acid therapeutics in haematological malignancies. Br J Haematol. 2011; 155: 3-13.
62. Shigdar S, Macdonald J, O'Connor M, et al. Aptamers as theranostic agents: modifications, serum stability and functionalisation. Sensors (Basel). 2013; 13: 13624-37.
63. Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov. 2010; 9: 537-50.
64. Keefe AD, Cload ST. SELEX with modified nucleotides. Curr Opin Chem Biol. 2008; 12: 448-56.
65. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008; 7: 771-82.
66. Prabhakar U, Maeda H, Jain RK, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 2013; 73: 2412-7.
67. Zhong Y, Meng F, Deng C, et al. Ligand-Directed Active Tumor-Targeting Polymeric Nanoparticles for Cancer Chemotherapy. Biomacromolecules. 2014.
68. Hollis CP, Weiss HL, Leggas M, et al. Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug delivery. J Control Release. 2013; 172: 12-21.
69. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010; 9: 615-27.
70. Bertrand N, Wu J, Xu X, et al. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014; 66: 2-25.
71. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2002; 2: 750-63.
72. Modery-Pawlowski CL, Gupta AS. Heteromultivalent ligand-decoration for actively targeted nanomedicine. Biomaterials. 2014; 35: 2568-79.
73. Hirsjarvi S, Passirani C, Benoit J-P. Passive and active tumor targeting with nanocarriers. Curr Drug Discov Technol. 2011; 8: 188-96.
74. Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2010; 148: 135-46.
75. Patriarca C, Macchi RM, Marschner AK, et al. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev. 2012; 38: 68-75.
76. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov. 2006; 5: 147-59.
77. Chari RVJ, Miller ML, Widdison WC. Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed Engl. 2014; 53: 3796-827.
78. Bouchard PR, Hutabarat RM, Thompson KM. Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxicol. 2010; 50: 237-57.
79. Dassie JP, Liu XY, Thomas GS, et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol. 2009; 27: 839-49.
80. Radom F, Jurek PM, Mazurek MP, et al. Aptamers: molecules of great potential. Biotechnol Adv. 2013; 31: 1260-74.
81. Panowksi S, Bhakta S, Raab H, et al. Site-specific antibody drug conjugates for cancer therapy. MAbs. 2014; 6: 34-45.
82. Zamay TN, Kolovskaya OS, Glazyrin YE, et al. DNA-aptamer targeting vimentin for tumor therapy in vivo. Nucleic Acid Ther. 2014; 24: 160-70.
83. Lehr C-M, Gabor F. Lectins and glycoconjugates in drug delivery and targeting. Adv Drug Deliv Rev. 2004; 56: 419-20.
84. Prescott JH, Enriquez P, Jung C, et al. Larch arabinogalactan for hepatic drug delivery: isolation and characterization of a 9 kDa arabinogalactan fragment. Carbohydr Res. 1995; 278: 113-28.
85. Roth F, De La Fuente AC, Vella JL, et al. Aptamer-mediated blockade of IL4Ralpha triggers apoptosis of MDSCs and limits tumor progression. Cancer Res. 2012; 72: 1373-83.
86. Yang L, DeBusk LM, Fukuda K, et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell. 2004; 6: 409-21.
87. van Kempen LC, Coussens LM. MMP9 potentiates pulmonary metastasis formation. Cancer Cell. 2002; 2: 251-2.
88. Mern DS, Hasskarl J, Burwinkel B. Inhibition of Id proteins by a peptide aptamer induces cell-cycle arrest and apoptosis in ovarian cancer cells. Br J Cancer. 2010; 103: 1237-44.
89. Mern DS, Hoppe-Seyler K, Hoppe-Seyler F, et al. Targeting Id1 and Id3 by a specific peptide aptamer induces E-box promoter activity, cell cycle arrest, and apoptosis in breast cancer cells. Breast Cancer Res Treat. 2010; 124: 623-33.
90. Zhang K, Sefah K, Tang L, et al. A novel aptamer developed for breast cancer cell internalization. ChemMedChem. 2012; 7: 79-84.
91. Kaur H, Li JJ, Bay B-H, et al. Investigating the antiproliferative activity of high affinity DNA aptamer on cancer cells. PLoS One. 2013; 8: e50964.
92. Ojima A, Matsui T, Maeda S, et al. DNA aptamer raised against advanced glycation end products inhibits melanoma growth in nude mice. Lab Invest. 2014; 94: 422-9.
93. Lee YJ, Han SR, Kim NY, et al. An RNA aptamer that binds carcinoembryonic antigen inhibits hepatic metastasis of colon cancer cells in mice. Gastroenterology. 2012; 143: 155-65.e8.
94. Huang Y-F, Sefah K, Bamrungsap S, et al. Selective photothermal therapy for mixed cancer cells using aptamer-conjugated nanorods. Langmuir. 2008; 24: 11860-5.
95. Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013; 65: 157-70.
96. Agudelo D, Bourassa P, Berube G, et al. Intercalation of antitumor drug doxorubicin and its analogue by DNA duplex: Structural features and biological implications. Int J Biol Macromol. 2014; 66: 144-50.
97. Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004; 56: 185-229.
98. Sussman D, Nix JC, Wilson C. The structural basis for molecular recognition by the vitamin B 12 RNA aptamer. Nat Struct Biol. 2000; 7: 53-7.
99. Zhu G, Meng L, Ye M, et al. Self-assembled aptamer-based drug carriers for bispecific cytotoxicity to cancer cells. Chem Asian J. 2012; 7: 1630-6.
100. Huang YF, Shangguan D, Liu H, et al. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem. 2009; 10: 862-8.
101. Hu Y, Duan J, Zhan Q, et al. Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro. PLoS One. 2012; 7: e31970.
102. Liu Z, Duan JH, Song YM, et al. Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. J Transl Med. 2012; 10: 148.
103. Subramanian N, Raghunathan V, Kanwar JR, et al. Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer. Mol Vis. 2012; 18: 2783-95.
104. Ray P, Cheek MA, Sharaf ML, et al. Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells. Nucleic Acid Ther. 2012; 22: 295-305.
105. Orilall MC, Wiesner U. Block copolymer based composition and morphology control in nanostructured hybrid materials for energy conversion and storage: solar cells, batteries, and fuel cells. Chem Soc Rev. 2011; 40: 520-35.
106. Zhang L, Radovic-Moreno AF, Alexis F, et al. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. ChemMedChem. 2007; 2: 1268-71.
107. Dhar S, Gu FX, Langer R, et al. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A. 2008; 105: 17356-61.
108. Xiao Z, Farokhzad OC. Aptamer-functionalized nanoparticles for medical applications: challenges and opportunities. ACS Nano. 2012; 6: 3670-6.
109. Farokhzad OC, Karp JM, Langer R. Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opin Drug Deliv. 2006; 3: 311-24.
110. Chan JM, Zhang L, Yuet KP, et al. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials. 2009; 30: 1627-34.
111. Zheng Y, Yu B, Weecharangsan W, et al. Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7alpha-APTADD to breast cancer cells. Int J Pharm. 2010; 390: 234-41.
112. Farokhzad OC, Jon S, Khademhosseini A, et al. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 2004; 64: 7668-72.
113. Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A. 2006; 103: 6315-20.
114. Vanhoefer U, Cao S, Harstrick A, et al. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP). Ann Oncol. 1997; 8: 1221-8.
115. Bates PJ, Laber DA, Miller DM, et al. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol. 2009; 86: 151-64.
116. Guo J, Gao X, Su L, et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials. 2011; 32: 8010-20.
117. Dicheva BM, Koning GA. Targeted thermosensitive liposomes: an attractive novel approach for increased drug delivery to solid tumors. Expert Opin Drug Deliv. 2014; 11: 83-100.
118. Deshpande PP, Biswas S, Torchilin VP. Current trends in the use of liposomes for tumor targeting. Nanomedicine (Lond). 2013; 8: 1509-28.
119. Yang T, Cui F-D, Choi M-K, et al. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm. 2007; 338: 317-26.
120. Er Y, Barnes TJ, Fornasiero D, et al. The encapsulation and release of guanosine from PEGylated liposomes. J Liposome Res. 2009; 19: 29-36.
121. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci. 2009; 30: 592-9.
122. Kang H, O'Donoghue MB, Liu H, et al. A liposome-based nanostructure for aptamer directed delivery. Chem Commun (Camb). 2010; 46: 249-51.
123. Xing H, Tang L, Yang X, et al. Selective Delivery of an Anticancer Drug with Aptamer-Functionalized Liposomes to Breast Cancer Cells and in vitro and in vivo. J Mater Chem B Mater Biol Med. 2013; 1: 5288-97.
124. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol. 2001; 11: 2319-31.
125. Bourrinet P, Bengele HH, Bonnemain B, et al. Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent. Invest Radiol. 2006; 41: 313-24.
126. Wang AZ, Bagalkot V, Vasilliou CC, et al. Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem. 2008; 3: 1311-5.
127. Jalalian SH, Taghdisi SM, Shahidi Hamedani N, et al. Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo. Eur J Pharm Sci. 2013; 50: 191-7.
128. Meng L, Zhang X, Lu Q, et al. Single walled carbon nanotubes as drug delivery vehicles: targeting doxorubicin to tumors. Biomaterials. 2012; 33: 1689-98.
129. Wang G, Uludag H. Recent developments in nanoparticle-based drug delivery and targeting systems with emphasis on protein-based nanoparticles. Expert Opin Drug Deliv. 2008; 5: 499-515.
130. Lee IH, An S, Yu MK, et al. Targeted chemoimmunotherapy using drug-loaded aptamer-dendrimer bioconjugates. J Control Release. 2011; 155: 435-41.
131. Li Z, Liu Z, Yin M, et al. Aptamer-capped multifunctional mesoporous strontium hydroxyapatite nanovehicle for cancer-cell-responsive drug delivery and imaging. Biomacromolecules. 2012; 13: 4257-63.
132. Sa LTM, Simmons S, Missailidis S, et al. Aptamer-based nanoparticles for cancer targeting. J Drug Target. 2013; 21: 427-34.
133. Xiao Z, Levy-Nissenbaum E, Alexis F, et al. Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection. ACS Nano. 2012; 6: 696-704.
134. Hao Z, Fan W, Hao J, et al. Efficient delivery of micro RNA to bone-metastatic prostate tumors by using aptamer-conjugated atelocollagen in vitro and in vivo. Drug Deliv. 2014: 1-8.
135. Aravind A, Jeyamohan P, Nair R, et al. AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery. Biotechnol Bioeng. 2012; 109: 2920-31.
136. Aravind A, Nair R, Raveendran S, et al. Aptamer conjugated paclitaxel and magnetic fluid loaded fluorescently tagged PLGA nanoparticles for targeted cancer therapy. J Magn Magn Mater. 2013; 344: 116-23.
137. Sivakumar B, Aswathy RG, Nagaoka Y, et al. Aptamer conjugated theragnostic multifunctional magnetic nanoparticles as a nanoplatform for pancreatic cancer therapy. RSC Adv. 2013; 3: 20579-98.
138. Zhang B, Luo Z, Liu J, et al. Cytochrome c end-capped mesoporous silica nanoparticles as redox-responsive drug delivery vehicles for liver tumor-targeted triplex therapy in vitro and in vivo. J Control Release. 2014; 192C: 192-201.
139. Zhang H, Hou L, Jiao X, et al. In vitro and in vivo evaluation of antitumor drug -loaded aptamer targeted single-walled carbon nanotubes system. Curr Pharm Biotechnol. 2014; doi: 10.2174/1389201015666140408123710. [Epub ahead of print].
140. Yang X, Liu X, Liu Z, et al. Near-infrared light-triggered, targeted drug delivery to cancer cells by aptamer gated nanovehicles. Adv Mater. 2012; 24: 2890-5.
141. Shiao YS, Chiu HH, Wu PH, et al. Aptamer-Functionalized Gold Nanoparticles As Photoresponsive Nanoplatform for Co-Drug Delivery. ACS Appl Mater Interfaces. 2014: doi:10.1021/am5026243. [Epub ahead of print].
142. Yu C, Hu Y, Duan J, et al. Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro. PLoS One. 2011; 6: e24077.
143. Wu C, Han D, Chen T, et al. Building a multifunctional aptamer-based DNA nanoassembly for targeted cancer therapy. J Am Chem Soc. 2013; 135: 18644-50.
144. Zhu G, Zheng J, Song E, et al. Self-assembled, aptamer-tethered DNA nanotrains for targeted transport of molecular drugs in cancer theranostics. Proc Natl Acad Sci U S A. 2013; 110: 7998-8003.
145. Zhao Z, Xu L, Shi X, et al. Recognition of subtype non-small cell lung cancer by DNA aptamers selected from living cells. Analyst. 2009; 134: 1808-14.
146. Thiel KW, Giangrande PH. Intracellular delivery of RNA-based therapeutics using aptamers. Ther Deliv. 2010; 1: 849-61.
147. Cerchia L, Esposito CL, Camorani S, et al. Coupling Aptamers to Short Interfering RNAs as Therapeutics. Pharmaceuticals. 2011; 4: 1434-49.
148. Ni X, Zhang Y, Ribas J, et al. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J Clin Invest. 2011; 121: 2383-90.
149. Chu TC, Marks JW, 3rd, Lavery LA, et al. Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res. 2006; 66: 5989-92.
150. McNamara JO, 2nd, Andrechek ER, Wang Y, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol. 2006; 24: 1005-15.
151. Bumcrot D, Manoharan M, Koteliansky V, et al. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol. 2006; 2: 711-9.
152. Zhou J, Bobbin ML, Burnett JC, et al. Current progress of RNA aptamer-based therapeutics. Front Genet. 2012; 3: 234.
153. Berezhnoy A, Castro I, Levay A, et al. Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity. J Clin Invest. 2014; 124: 188-97.
154. Lai W-Y, Wang W-Y, Chang Y-C, et al. Synergistic inhibition of lung cancer cell invasion, tumor growth and angiogenesis using aptamer-siRNA chimeras. Biomaterials. 2014; 35: 2905-14.
155. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009; 27: 5848-56.
156. Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. Science. 2005; 309: 1519-24.
157. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 2012; 4: 143-59.
158. Garofalo M, Condorelli GL, Croce CM, et al. MicroRNAs as regulators of death receptors signaling. Cell Death Differ. 2010; 17: 200-8.
159. Esposito CL, Cerchia L, Catuogno S, et al. Multifunctional Aptamer-miRNA Conjugates for Targeted Cancer Therapy. Mol Ther. 2014; 22: 1151-63.
160. Yu J-Y, DeRuiter SL, Turner DL. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci U S A. 2002; 99: 6047-52.
161. Wang Z, Rao DD, Senzer N, et al. RNA interference and cancer therapy. Pharm Res. 2011; 28: 2983-95.
162. Rao DD, Vorhies JS, Senzer N, et al. siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev. 2009; 61: 746-59.
163. Frei E, 3rd. Combination cancer therapy: Presidential address. Cancer Res. 1972; 32: 2593-607.
164. Walsh C. Molecular mechanisms that confer antibacterial drug resistance. Nature. 2000; 406: 775-81.
165. Hongrapipat J, Kopeckova P, Liu J, et al. Combination chemotherapy and photodynamic therapy with fab' fragment targeted HPMA copolymer conjugates in human ovarian carcinoma cells. Mol Pharm. 2008; 5: 696-709.
166. Wiradharma N, Tong YW, Yang Y-Y. Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect. Biomaterials. 2009; 30: 3100-9.
167. Yadav S, van Vlerken LE, Little SR, et al. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother Pharmacol. 2009; 63: 711-22.
168. Liu N, Zhou C, Zhao J, et al. Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a MUC1 aptamer-let-7i chimera. Cancer Invest. 2012; 30: 577-82.
169. Kim E, Jung Y, Choi H, et al. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials. 2010; 31: 4592-9.
170. Wang AZ, Farokhzad OC. Current progress of aptamer-based molecular imaging. J Nucl Med. 2014; 55: 353-6.
171. Mishra G, Giri D, Li MS, et al. Role of loop entropy in the force induced melting of DNA hairpin. J Chem Phys. 2011; 135: 035102.
172. Turney K, Drake TJ, Smith JE, et al. Functionalized nanoparticles for liquid atmospheric pressure matrix-assisted laser desorption/ionization peptide analysis. Rapid Commun Mass Spectrom. 2004; 18: 2367-74.
173. Fang X, Sen A, Vicens M, et al. Synthetic DNA aptamers to detect protein molecular variants in a high-throughput fluorescence quenching assay. Chembiochem. 2003; 4: 829-34.
174. Scaglioni PP, Pandolfi PP. Medicine: taking apart a cancer protein. Nature. 2003; 426: 512-3.
175. Khan H, Missailidis S. Aptamers in oncology: a diagnostic perspective. Gene Ther Mol Bio. 2008; 12: 111-28.
176. Wadas TJ, Wong EH, Weisman GR, et al. Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr Pharm Des. 2007; 13: 3-16.
177. Li WP, Lewis JS, Kim J, et al. DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy. Bioconjug Chem. 2002; 13: 721-8.
178. Boswell CA, Sun X, Niu W, et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem. 2004; 47: 1465-74.
179. Wu Y, Zhang X, Xiong Z, et al. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med. 2005; 46: 1707-18.
180. Li J, Zheng H, Bates PJ, et al. Aptamer imaging with Cu-64 labeled AS1411: preliminary assessment in lung cancer. Nucl Med Biol. 2014; 41: 179-85.
181. Charlton J, Sennello J, Smith D. In vivo imaging of inflammation using an aptamer inhibitor of human neutrophil elastase. Chem Biol. 1997; 4: 809-16.
182. You XG, Tu R, Peng ML, et al. Molecular magnetic resonance probe targeting VEGF165: preparation and in vitro and in vivo evaluation. Contrast Media Mol Imaging. 2014; doi: 10.1002/cmmi.1584. [Epub ahead of print].
183. Sauter ER, Nesbit M, Watson JC, et al. Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res. 1999; 5: 775-82.
184. Jayson GC, Zweit J, Jackson A, et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst. 2002; 94: 1484-93.
185. Nagengast WB, de Korte MA, Oude Munnink TH, et al. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med. 2010; 51: 761-7.
186. Anderson CR, Rychak JJ, Backer M, et al. scVEGF microbubble ultrasound contrast agents: a novel probe for ultrasound molecular imaging of tumor angiogenesis. Invest Radiol. 2010; 45: 579-85.
187. Chen XS. Introducing Theranostics Journal - From the Editor-in-Chief. Theranostics. 2011; 1: 1-2.
188. Casciaro S. Theranostic applications: Non-ionizing cellular and molecular imaging through innovative nanosystems for early diagnosis and therapy. World J Radiol. 2011; 3: 249-55.
189. Palekar-Shanbhag P, Jog SV, Chogale MM, et al. Theranostics for cancer therapy. Curr Drug Deliv. 2013; 10: 357-62.
190. Fleuren ED, Versleijen-Jonkers YM, Heskamp S, et al. Theranostic applications of antibodies in oncology. Mol Oncol. 2014; 8: 799-812.
191. Chen F, Hong H, Zhang Y, et al. In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles. ACS Nano. 2013; 7: 9027-39.
192. Wang J, Tian S, Petros RA, et al. The complex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies. J Am Chem Soc. 2010; 132: 11306-13.
193. Shi H, Ye X, He X, et al. AuAg/Au nanoparticles assembled with activatable aptamer probes as smart "nano-doctors" for image-guided cancer thermotherapy. Nanoscale. 2014; 6: 8754-61.
194. Fan Z, Senapati D, Singh AK, et al. Theranostic magnetic core-plasmonic shell star shape nanoparticle for the isolation of targeted rare tumor cells from whole blood, fluorescence imaging, and photothermal destruction of cancer. Mol Pharm. 2013; 10: 857-66.
195. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976; 194: 23-8.
196. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumors: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008; 8: 755-68.
197. Nguyen-Khac F, Lesty C, Eclache V, et al. Chromosomal abnormalities in transformed Ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations. Genes Chromosomes Cancer. 2010; 49: 919-27.
198. Shackleton M, Quintana E, Fearon ER, et al. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 2009; 138: 822-9.
199. Lee HE, Kim JH, Kim YJ, et al. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer. 2011; 104: 1730-8.
200. Beck B, Driessens G, Goossens S, et al. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumors. Nature. 2011; 478: 399-403.
201. Nguyen LV, Vanner R, Dirks P, et al. Cancer stem cells: an evolving concept. Nat Rev Cancer. 2012; 12: 133-43.
202. Jiang W, Peng J, Zhang Y, et al. The Implications of Cancer Stem Cells for Cancer Therapy. Int J Mol Sci. 2012; 13: 16636-57.
203. Vermeulen L, de Sousa e Melo F, Richel DJ, et al. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol. 2012; 13: e83-9.
204. Chaffer CL, Brueckmann I, Scheel C, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A. 2011; 108: 7950-5.
205. Scheel C, Eaton EN, Li SH-J, et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell. 2011; 145: 926-40.
206. Vermeulen L, de Sousa e Melo F, Richel DJ, et al. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol. 2012; 13: e83-e89.
207. Yang YM, Chang JW. Current status and issues in cancer stem cell study. Cancer Invest. 2008; 26: 741-55.
208. de Sousa EM, Vermeulen L, Richel D, et al. Targeting Wnt signaling in colon cancer stem cells. Clin Cancer Res. 2011; 17: 647-53.
209. Aulmann S, Waldburger N, Penzel R, et al. Reduction of CD44(+)/CD24(-) breast cancer cells by conventional cytotoxic chemotherapy. Hum Pathol. 2010; 41: 574-81.
210. Resetkova E, Reis-Filho JS, Jain RK, et al. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat. 2010; 123: 97-108.
211. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 2008; 10: R25.
212. Ghods AJ, Irvin D, Liu G, et al. Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells. Stem Cells. 2007; 25: 1645-53.
213. Francipane MG, Chandler J, Lagasse E. Cancer Stem Cells: A Moving Target. Curr Pathobiol Rep. 2013; 1: 111-18.
214. Williams K, Motiani K, Giridhar PV, et al. CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp Biol Med (Maywood). 2013; 238: 324-38.
215. Koren A, Motaln H, Cufer T. Lung cancer stem cells: a biological and clinical perspective. Cell Oncol (Dordr). 2013; 36: 265-75.
216. Singh SR. Gastric cancer stem cells: A novel therapeutic target. Cancer Lett. 2013; 338: 110-9.
217. McAuliffe SM, Morgan SL, Wyant GA, et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci U S A. 2012; 109: E2939-48.
218. Levina V, Marrangoni A, Wang T, et al. Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Res. 2010; 70: 338-46.
219. Li L, Xiang D, Shigdar S, et al. Epithelial cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cells. Int J Nanomedicine. 2014; 9: 1083-96.